Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael D. Robek
Albany Medical College, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Carogen Corporation
Payment for services (e.g., consulting fees, honoraria, paid authorship)
A goal of the funded research is to evaluate the immunogenicity and efficacy of a vaccine platform based on ”virus-like vesicles” (VLV). Dr. Robek is the inventor of intellectual property related to the VLV platform that has been licensed from Yale University to CaroGen Corporation, which is seeking to commercialize this technology. Dr. Robek has a consulting agreement with CaroGen to serve on the company’s Scientific Advisory Board. He has also been reimbursed for travel by CaroGen. It was determined by the AMC Conflict of Interest committee that these interests represent a Financial Conflict of Interest as defined by NIH and the AMC Conflict of Interest Policy.
Highly Attenuated Vesiculovirus-based Vectors as HBV Therapeutic Vaccines
Chronic hepatitis B virus (HBV) infection affects more than 240 million people worldwide, and is a significant health problem because it substantially increases the risk for developing liver diseases such as cirrhosis and hepatocellular carcinoma. Because current therapies for chronic HBV typically do not eliminate the virus from the liver, new approaches to cure HBV infection are needed. The research proposed in this application is directed at developing novel immunotherapeutic vaccines for treatment of this disease.
Filed on March 08, 2016.
Tell us what you know about Michael D. Robek's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Michael D. Robek filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Michael Robek | Albany Medical College | Conflict of Interest | Carogen Corporation | $0 - $4,999 |
| Michael D. Robek | Albany Medical College | Conflict of Interest | Carogen Corporation | $0 - $4,999 |
| Michael Robek | Albany Medical College | Conflict of Interest | Carogen Corporation | Value cannot be readily determined |
| Michael D. Robek | Albany Medical College | Conflict of Interest | Carogen Corporation | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.